"Designing Growth Strategies is in our DNA"
Region : | Published Date: Upcoming | Report ID: FBI100981| Status : Pipeline
Bronchopulmonary dysplasia (BPD) is a type of chronic lung disease that affects premature infants who have respiratory distress syndrome and have low birth weight (LBW) shortly after birth. In 2018, according to the report published by National Jewish Health, it was estimated that 40% of new-born babies developed bronchopulmonary dysplasia every year. Wheezing, bluish discoloration of the skin around nails and lips due to lack of oxygen in the blood, reoccurring lung infections and rapid breathing are some of the symptoms shown by infants having bronchopulmonary dysplasia
Bronchopulmonary dysplasia can be diagnosed using chest X-rays or through the usage of pulse oximetry in infants who need continuous oxygen supply due to severe respiratory issues. Other diagnostic measures also include continuous heart monitoring to check any complications of pulmonary hypertension associated with bronchopulmonary dysplasia. Medications such as diuretic medicines which includes furosemide, chlorothiazide, and spironolactone that help in the removal of excess fluid from the infant’s body; anti-inflammatory drugs like montelukast and inhaled corticosteroids such as budesonide and fluticasone, additionally, the usage of ventilators support is some of the options available for the treatment of bronchopulmonary dysplasia in premature infants.
Pharmaceutical companies, along with government-funded organizations, have been focusing on studying and developing new treatment options for bronchopulmonary dysplasia. For instance; PNEUMOSTEM, which is being studied by MEDIPOST Co., Ltd., is currently in phase-2 clinical trials for the study of the efficacy and safety of PNEUMOSTEM for the prevention and treatment of severe bronchopulmonary dysplasia (severe BPD) in premature infants
To get details on market share, speak to our analyst
At present, around 70% of the pipeline candidates for Bronchopulmonary Dysplasia are in the phase-1 and phase- stage. Government-funded organizations sponsor more than half of the studies.
The report on ‘Bronchopulmonary Dysplasia– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bronchopulmonary Dysplasia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bronchopulmonary Dysplasia.
The report on ‘Bronchopulmonary Dysplasia– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.